Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2214-2220

  Schlaich, Markus P ^a,b   Bart, Bradley ^c   Hering, Dagmara ^a,d   Walton, Anthony ^a   Marusic, Petra ^a   Mahfoud, Felix ^e   Böhm, Michael ^e   Lambert, Elisabeth A ^a,b   Krum, Henry ^f   Sobotka, Paul A ^g,h   Schmieder, Roland E ⁱ   Ika Sari, Carolina ^a   Eikelis, Nina ^a   Straznicky, Nora ^a   Lambert, Gavin W ^a,b   Esler, Murray D ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e SAARLAND UNIVERSITY   (Germany)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h Ardian Inc   (United States)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

End stage renal disease; Hypertension; Renal denervation; Sympathetic

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; VASODILATOR AGENT;

ADULT; ARTICLE; ATROPHY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CATHETER; CATHETER ABLATION; CLINICAL ARTICLE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FAILURE; KIDNEY NERVE; MALE; NERVE CONDUCTION; NEUROGRAPHY; NORADRENALIN BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL ARTERY ATROPHY; RENAL REPLACEMENT THERAPY; SAFETY; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; ADRENERGIC SYSTEM; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; FEMALE; HYPERTENSION, RENAL; INNERVATION; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SURGERY; SYMPATHECTOMY; TIME; TREATMENT OUTCOME;

BLOOD PRESSURE; CATHETER ABLATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, RENAL; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885676378     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.218     Document Type: Article

References (28)

1. G.F. DiBona, and U.C. Kopp Neural control of renal function Physiol Rev 77 1997 75 197
2. M. Esler, G. Jennings, and G. Lambert Noradrenaline release and the pathophysiology of primary human hypertension Am J Hypertens 2 1989 140S 146S
3. M.P. Schlaich, E. Lambert, and D.M. Kaye Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation Hypertension 43 2004 169 175
4. M.P. Schlaich, D.M. Kaye, E. Lambert, M. Sommerville, F. Socratous, and M.D. Esler Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy Circulation 108 2003 560 565
5. A.S. Zanchetti Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension Circulation 56 1977 691 698
6. E. Bell-Reuss, D.L. Trevino, and C.W. Gottschalk Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption J Clin Invest 57 1976 1104 1107
7. H. Kirchheim, H. Ehmke, and P. Persson Sympathetic modulation of renal hemodynamics, renin release and sodium excretion Klin Wochenschr 67 1989 858 864
8. V. Kon Neural control of renal circulation Miner Electrolyte Metab 15 1989 33 43
9. V.M. Campese, and E. Kogosov Renal afferent denervation prevents hypertension in rats with chronic renal failure Hypertension 25 1995 878 882
10. G.F. DiBona Neural control of the kidney: past, present, and future Hypertension 41 2003 621 624
11. M.P. Schlaich, P.A. Sobotka, H. Krum, R. Whitbourn, A. Walton, and M.D. Esler Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept Hypertension 54 2009 1195 1201
12. C. Zoccali, F. Mallamaci, and S. Parlongo Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease Circulation 105 2002 1354 1359
13. M.J. Klag, P.K. Whelton, and B.L. Randall Blood pressure and end-stage renal disease in men N Engl J Med 334 1996 13 18
14. S.G. Rostand, J.D. Brunzell, ROd Cannon, and R.G. Victor Cardiovascular complications in renal failure [editorial] J Am Soc Nephrol 2 1991 1053 1062
15. C.A. Herzog, J.Z. Ma, and A.J. Collins Poor long-term survival after acute myocardial infarction among patients on long-term dialysis N Engl J Med 339 1998 799 805
16. C.M. O'Seaghdha, V. Perkovic, and T.H. Lam Asia Pacific Cohort Studies Collaboration. Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region Hypertension 54 2009 509 515
17. R.L. Converse Jr., T.N. Jacobsen, and R.D. Toto Sympathetic overactivity in patients with chronic renal failure N Engl J Med 327 1992 1912 1918
18. M. Hausberg, M. Kosch, and P. Harmelink Sympathetic nerve activity in end-stage renal disease Circulation 106 2002 1974 1979
19. M.P. Schlaich, H. Krum, P.A. Sobotka, and M.D. Esler Renal denervation and hypertension Am J Hypertens 24 2011 635 642
20. M.P. Schlaich, F. Socratous, and S. Hennebry Sympathetic activation in chronic renal failure J Am Soc Nephrol 20 2009 933 939
21. H. Krum, M. Schlaich, and R. Whitbourn Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
22. M.D. Esler, H. Krum, P.A. Sobotka, M.P. Schlaich, R.E. Schmieder, and M. Bohm Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet 376 2010 1903 1909
23. M.P. Schlaich, P.A. Sobotka, H. Krum, E. Lambert, and M.D. Esler Renal sympathetic-nerve ablation for uncontrolled hypertension N Engl J Med 361 2009 932 934
24. M.P. Schlaich, N. Straznicky, and M. Grima Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 29 2011 991 996
25. F. Mahfoud, M. Schlaich, and I. Kindermann Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study Circulation 123 2011 1940 1946
26. D. Kaye, J. Thompson, G. Jennings, and M. Esler Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation Circulation 88 1993 1101 1109
27. M. Petersson, P. Friberg, G. Eisenhofer, G. Lambert, and B. Rundqvist Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure Eur Heart J 26 2005 906 913
28. D.M. Kaye, J. Lefkovits, G.L. Jennings, P. Bergin, A. Broughton, and M.D. Esler Adverse consequences of high sympathetic nervous activity in the failing human heart J Am Coll Cardiol 26 1995 1257 1263